Atomera Earnings Call: Tech Breakthroughs, Cash Burn Risks

Atomera Inc ((ATOM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Atomera’s latest earnings call painted a picture of sharp technical momentum against a stubbornly weak financial backdrop. Management highlighted breakthroughs in several high‑growth semiconductor segments, yet admitted that these wins have not yet produced material revenue. Investors are left weighing strong technology validation against cash burn, dilution and uncertain commercialization timelines.

Gate-All-Around Breakthrough Targets Leading-Edge Foundries

Atomera reported definitive silicon results showing its MST film can be integrated into nanosheet GAA structures while outperforming silicon arsenic as a diffusion blocker. The company expects leading GAA players, including top foundries and a new Japanese manufacturer, to evaluate the technology over the coming quarters, potentially setting up future implementation.

Broader Market Push Across Memory, RF and Power

Management detailed parallel progress in several end markets, including DRAM, RF‑SOI, power devices and GaN. Wafer‑based offerings are under way for DRAM and RF‑SOI, while MST is now running on GaN‑on‑silicon wafers for a first commercial GaN customer, broadening the company’s optionality beyond logic.

GaN Program Gains First External Funding Pathway

The company’s GaN‑on‑silicon concept paper advanced to the proposal stage within a Power America program, marking Atomera’s first move toward external development funding. Management emphasized that the process has already generated multiple letters of support from prospective customers and partners, signaling industry interest in its GaN roadmap.

Record Wafer Runs Signal Rising Customer Engagement

Atomera said it initiated a record number of wafer runs in 2025, many destined for customers’ own fabs rather than just internal labs. These wafers will now enter customer test cycles that typically last six to nine months, creating a pipeline of potential joint development agreements and future licensing deals, albeit with long lead times.

R&D Spending Rises with AI-Driven Efficiency Gains

R&D expense climbed to $10.2 million in 2025, up 8.4% year over year, as Atomera funded multiple device fabrication vendors and new wafer runs. Management argued that AI‑driven development and TCAD simulations are sharpening experiment design, allowing more learning per dollar even as absolute R&D spending trends higher.

Quarterly Loss Narrows on Bonus Accrual Reversal

Non‑GAAP net loss in Q4 2025 improved to $3.3 million, or $0.10 per share, versus $4.4 million in Q3 and $3.9 million a year earlier. The roughly 25% sequential and 15% annual improvements were helped by the reversal of an executive bonus accrual, a benefit investors should view as non‑recurring.

Strategic OEM Partnership Aims to Speed MST Adoption

Atomera unveiled a strategic partnership with a major equipment OEM to accelerate validation and potential adoption of MST in advanced‑node manufacturing. By embedding MST into the OEM’s ecosystem, the company hopes to leverage the partner’s industry influence to lower barriers for customer trials and eventual production use.

Revenue Remains Negligible Despite Technical Wins

Despite the flurry of technical activity, 2025 revenue totaled just $65,000, derived from NRE fees and MST CAD licensing. Management signaled that Q1 2026 revenue will remain minimal at only $50,000 to $100,000, underscoring that commercial MST product adoption is still in its infancy.

Net Losses and Operating Costs Continue to Climb

GAAP net loss rose to $20.2 million in 2025 from $18.4 million, while non‑GAAP net loss increased to $16.1 million from $15.4 million. Operating expenses also moved higher, with GAAP opex up roughly 8.3% to $20.9 million, reflecting Atomera’s decision to invest ahead of expected commercialization.

Cash Burn and Shrinking Cash Pile Raise Runway Questions

Year‑end cash, cash equivalents and short‑term investments fell to $19.2 million from $26.7 million, a 28.1% decline. The company used $14.9 million of cash in operating activities during 2025, including $3.2 million in Q4, leaving investors focused on how long the current balance can sustain the business.

Equity Dilution Highlights Financing Risk and Weak Stock

To support operations, Atomera sold about 1.6 million shares in 2025 via an at‑the‑market program for net proceeds of roughly $7.6 million at an average price of $5.15. After year‑end it issued another 1.3 million shares for about $3.2 million at a much lower $2.47 average, bringing shares outstanding to 32.4 million and highlighting both dilution and share price pressure.

Commercialization Still Prospective with Long Sales Cycles

Management stressed that, despite strong technical validation, meaningful revenue depends on customers integrating MST into production, a process that is inherently slow and complex. With customer test cycles lasting six to nine months and no major licenses yet booked, commercial deals remain prospective rather than visible in the income statement.

Higher 2026 Expense Outlook Tied to Bonus Accruals

Atomera guided to 2026 non‑GAAP operating expenses of about $18.5 million, which appears up 17% versus 2025’s $15.9 million, but closer to 8% higher on a normalized basis. The increase largely reflects the timing of executive bonus accruals, with about $669,000 of 2025 bonus potentially payable in 2026 if ambitious commercial goals are achieved.

Reliance on Partners Adds Execution Complexity

The company acknowledged a prior setback with a major partner and conceded it remains dependent on large strategic partners and OEMs to drive MST trials and adoption. While new collaborations and OEM ties expand reach, this reliance adds another layer of execution risk on top of already demanding technology and qualification hurdles.

Guidance Focuses on Tight Near-Term View and Cost Control

For Q1 2026, Atomera expects just $50,000 to $100,000 in revenue from MST wafer shipments and offered no longer‑term revenue outlook. The company projects 2026 non‑GAAP operating expenses of about $18.5 million and highlighted $19.2 million of year‑end liquidity, $14.9 million of 2025 operating cash use and 32.4 million shares outstanding as key metrics for investors to monitor.

Atomera’s call balanced optimism over technology traction with realism about the financial strain of staying pre‑revenue. The company is building promising positions in GAA, GaN and other niches, but investors must tolerate ongoing losses, dilution and timeline uncertainty while waiting for proof that these technical wins can translate into sustainable, high‑margin licensing revenue.